PI3K/AKT/mTOR Signaling Pathway Is Required for JCPyV Infection in Primary Astrocytes

被引:8
|
作者
Wilczek, Michael P. [1 ]
Armstrong, Francesca J. [1 ]
Mayberry, Colleen L. [1 ]
King, Benjamin L. [1 ,2 ]
Maginnis, Melissa S. [1 ,2 ]
机构
[1] Univ Maine, Dept Mol & Biomed Sci, Orono, ME 04469 USA
[2] Univ Maine, Grad Sch Biomed Sci & Engn, Orono, ME 04469 USA
基金
美国国家卫生研究院;
关键词
JC polyomavirus; PML; astrocytes; SVGA cells; primary cells; PI3K; AKT; mTOR; rapamycin; wortmannin; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; LARGE T-ANTIGEN; JC VIRUS-DNA; MATRIX-METALLOPROTEINASE EXPRESSION; MULTIPLE-SCLEROSIS; BK POLYOMAVIRUS; GENE-EXPRESSION; CELL BIOLOGY; GLIAL-CELLS; PROTEIN;
D O I
10.3390/cells10113218
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Astrocytes are a main target of JC polyomavirus (JCPyV) in the central nervous system (CNS), where the destruction of these cells, along with oligodendrocytes, leads to the fatal disease progressive multifocal leukoencephalopathy (PML). There is no cure currently available for PML, so it is essential to discover antivirals for this aggressive disease. Additionally, the lack of a tractable in vivo models for studying JCPyV infection makes primary cells an accurate alternative for elucidating mechanisms of viral infection in the CNS. This research to better understand the signaling pathways activated in response to JCPyV infection reveals and establishes the importance of the PI3K/AKT/mTOR signaling pathway in JCPyV infection in primary human astrocytes compared to transformed cell lines. Using RNA sequencing and chemical inhibitors to target PI3K, AKT, and mTOR, we have demonstrated the importance of this signaling pathway in JCPyV infection of primary astrocytes not observed in transformed cells. Collectively, these findings illuminate the potential for repurposing drugs that are involved with inhibition of the PI3K/AKT/mTOR signaling pathway and cancer treatment as potential therapeutics for PML, caused by this neuroinvasive virus.
引用
收藏
页数:25
相关论文
共 50 条
  • [21] Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects
    Zhang, Xiaowei
    Liu, Yuanbo
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2020, 19 (03) : 165 - 173
  • [22] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05) : 335 - 342
  • [23] The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma
    Fulda, S.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (06) : 729 - 737
  • [24] TDRG1 functions in testicular seminoma are dependent on the PI3K/Akt/mTOR signaling pathway
    Wang, Yong
    Gan, Yu
    Tan, Zhengyu
    Zhou, Jun
    Kitazawa, Riko
    Jiang, Xianzhen
    Tang, Yuxin
    Yang, Jianfu
    ONCOTARGETS AND THERAPY, 2016, 9 : 409 - 420
  • [25] Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
    Markman, Ben
    Dienstmann, Rodrigo
    Tabernero, Josep
    ONCOTARGET, 2010, 1 (07) : 530 - 543
  • [26] PI3K/Akt/mTOR pathway as a target for cancer therapy
    Morgensztern, D
    McLeod, HL
    ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
  • [27] Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
    Sun, Eun Jin
    Wankell, Miriam
    Palamuthusingam, Pranavan
    McFarlane, Craig
    Hebbard, Lionel
    BIOMEDICINES, 2021, 9 (11)
  • [28] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
    Glaviano, Antonino
    Foo, Aaron S. C.
    Lam, Hiu Y.
    Yap, Kenneth C. H.
    Jacot, William
    Jones, Robert H.
    Eng, Huiyan
    Nair, Madhumathy G.
    Makvandi, Pooyan
    Geoerger, Birgit
    Kulke, Matthew H.
    Baird, Richard D.
    Prabhu, Jyothi S.
    Carbone, Daniela
    Pecoraro, Camilla
    Teh, Daniel B. L.
    Sethi, Gautam
    Cavalieri, Vincenzo
    Lin, Kevin H.
    Javidi-Sharifi, Nathalie R.
    Toska, Eneda
    Davids, Matthew S.
    Brown, Jennifer R.
    Diana, Patrizia
    Stebbing, Justin
    Fruman, David A.
    Kumar, Alan P.
    MOLECULAR CANCER, 2023, 22 (01)
  • [29] Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance
    Ediriweera, Meran Keshawa
    Tennekoon, Kamani Hemamala
    Samarakoon, Sameera Ranganath
    SEMINARS IN CANCER BIOLOGY, 2019, 59 : 147 - 160
  • [30] The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines
    Mardanshahi, Alireza
    Gharibkandi, Nasrin Abbasi
    Vaseghi, Samaneh
    Abedi, Seyed Mohammad
    Molavipordanjani, Sajjad
    MOLECULAR BIOLOGY REPORTS, 2021, 48 (08) : 6167 - 6180